Jennifer M Cassano1, John G Kennedy2, Keir A Ross2, Ethan J Fraser2, Margaret B Goodale1, Lisa A Fortier3. 1. Department of Clinical Sciences, Cornell University College of Veterinary Medicine, VMC C3-181, Ithaca, NY, 14853, USA. 2. Department of Foot and Ankle Surgery, Hospital for Special Surgery, New York, NY, 10021, USA. 3. Department of Clinical Sciences, Cornell University College of Veterinary Medicine, VMC C3-181, Ithaca, NY, 14853, USA. laf4@cornell.edu.
Abstract
PURPOSE: Bone marrow concentrate (BMC) and platelet-rich plasma (PRP) are used extensively in regenerative medicine. The aim of this study was to determine differences in the cellular composition and cytokine concentrations of BMC and PRP and to compare two commercial BMC systems in the same patient cohort. METHODS: Patients (29) undergoing orthopaedic surgery were enrolled. Bone marrow aspirate (BMA) was processed to generate BMC from two commercial systems (BMC-A and BMC-B). Blood was obtained to make PRP utilizing the same system as BMC-A. Bone marrow-derived samples were cultured to measure colony-forming units, and flow cytometry was performed to assess mesenchymal stem cell (MSC) markers. Cellular concentrations were assessed for all samples. Catabolic cytokines and growth factors important for cartilage repair were measured using multiplex ELISA. RESULTS: Colony-forming units were increased in both BMCs compared to BMA (p < 0.0001). Surface markers were consistent with MSCs. Platelet counts were not significantly different between BMC-A and PRP, but there were differences in leucocyte concentrations. TGF-β1 and PDGF were not different between BMC-A and PRP. IL-1ra concentrations were greater (p = 0.0018) in BMC-A samples (13,432 pg/mL) than in PRP (588 pg/mL). The IL-1ra/IL-1β ratio in all BMC samples was above the value reported to inhibit IL-1β. CONCLUSIONS: The bioactive factors examined in this study have differing clinical effects on musculoskeletal tissue. Differences in the cellular and cytokine composition between PRP and BMC and between BMC systems should be taken into consideration by the clinician when choosing a biologic for therapeutic application. LEVEL OF EVIDENCE: Clinical, Level II.
PURPOSE: Bone marrow concentrate (BMC) and platelet-rich plasma (PRP) are used extensively in regenerative medicine. The aim of this study was to determine differences in the cellular composition and cytokine concentrations of BMC and PRP and to compare two commercial BMC systems in the same patient cohort. METHODS:Patients (29) undergoing orthopaedic surgery were enrolled. Bone marrow aspirate (BMA) was processed to generate BMC from two commercial systems (BMC-A and BMC-B). Blood was obtained to make PRP utilizing the same system as BMC-A. Bone marrow-derived samples were cultured to measure colony-forming units, and flow cytometry was performed to assess mesenchymal stem cell (MSC) markers. Cellular concentrations were assessed for all samples. Catabolic cytokines and growth factors important for cartilage repair were measured using multiplex ELISA. RESULTS: Colony-forming units were increased in both BMCs compared to BMA (p < 0.0001). Surface markers were consistent with MSCs. Platelet counts were not significantly different between BMC-A and PRP, but there were differences in leucocyte concentrations. TGF-β1 and PDGF were not different between BMC-A and PRP. IL-1ra concentrations were greater (p = 0.0018) in BMC-A samples (13,432 pg/mL) than in PRP (588 pg/mL). The IL-1ra/IL-1β ratio in all BMC samples was above the value reported to inhibit IL-1β. CONCLUSIONS: The bioactive factors examined in this study have differing clinical effects on musculoskeletal tissue. Differences in the cellular and cytokine composition between PRP and BMC and between BMC systems should be taken into consideration by the clinician when choosing a biologic for therapeutic application. LEVEL OF EVIDENCE: Clinical, Level II.
Authors: Richard Cuthbert; Sally A Boxall; Hiang Boon Tan; Peter V Giannoudis; Dennis McGonagle; Elena Jones Journal: Cytotherapy Date: 2012-01-24 Impact factor: 5.414
Authors: Lisa A Fortier; Hollis G Potter; Ellen J Rickey; Lauren V Schnabel; Li Foong Foo; Leroy R Chong; Tracy Stokol; Jon Cheetham; Alan J Nixon Journal: J Bone Joint Surg Am Date: 2010-08-18 Impact factor: 5.284
Authors: Lauren V Schnabel; Hussni O Mohammed; Brian J Miller; William G McDermott; May S Jacobson; Kelly S Santangelo; Lisa A Fortier Journal: J Orthop Res Date: 2007-02 Impact factor: 3.494
Authors: J U Yoo; T S Barthel; K Nishimura; L Solchaga; A I Caplan; V M Goldberg; B Johnstone Journal: J Bone Joint Surg Am Date: 1998-12 Impact factor: 5.284
Authors: Christopher J Centeno; Dan Busse; John Kisiday; Cristin Keohan; Michael Freeman; David Karli Journal: Pain Physician Date: 2008 May-Jun Impact factor: 4.965
Authors: G Filardo; E Kon; A Roffi; B Di Matteo; M L Merli; M Marcacci Journal: Knee Surg Sports Traumatol Arthrosc Date: 2013-11-26 Impact factor: 4.342
Authors: Venkata P Mantripragada; Nicolas S Piuzzi; Jaiben George; Wesley Bova; Mitchell Ng; Cynthia Boehm; George F Muschler Journal: Regen Med Date: 2019-07-19 Impact factor: 3.806
Authors: Constance R Chu; Lisa A Fortier; Ashley Williams; Karin A Payne; Taralyn M McCarrel; Megan E Bowers; Diego Jaramillo Journal: J Bone Joint Surg Am Date: 2018-01-17 Impact factor: 5.284